{"id":"NCT00083174","sponsor":"NCIC Clinical Trials Group","briefTitle":"Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer","officialTitle":"A Phase III Randomized Study of Exemestane Versus Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-12-03","primaryCompletion":"2011-03-25","completion":"2018-01-22","firstPosted":"2004-05-17","resultsPosted":"2013-05-20","lastUpdate":"2023-08-25"},"enrollment":4560,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Breast Cancer"],"interventions":[{"type":"DRUG","name":"exemestane","otherNames":[]}],"arms":[{"label":"Exemestane","type":"OTHER"}],"summary":"RATIONALE: The MAP.3 study was designed to test whether hormone therapy using exemestane may prevent breast cancer by blocking the production of estrogen.\n\nPURPOSE: The study protocol was amended in May 2011 and the current purpose of the study is to allow all study participants the opportunity to complete 5 years of exemestane.","primaryOutcome":{"measure":"Percentage of Women With Serious Adverse Events","timeFrame":"5 years open-label extension period","effectByArm":[{"arm":"Open-label Extension: Exemestane","deltaMin":0,"sd":null}],"pValues":[]},"eligibility":{"minAge":"35 Years","sex":"FEMALE","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":76,"countries":["United States","Canada","France","Puerto Rico"]},"refs":{"pmids":["17593981","18269782","21639806","24711552"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":39,"n":2240},"commonTop":["hot flashes","Pain Joint","fatigue","sweating","hypertension"]}}